Literature DB >> 22896678

Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.

Chih-Jen Wei1, Hadi M Yassine, Patrick M McTamney, Jason G D Gall, James R R Whittle, Jeffrey C Boyington, Gary J Nabel.   

Abstract

The immune system responds to influenza infection by producing neutralizing antibodies to the viral surface protein, hemagglutinin (HA), which regularly changes its antigenic structure. Antibodies that target the highly conserved stem region of HA neutralize diverse influenza viruses and can be elicited through vaccination in animals and humans. Efforts to develop universal influenza vaccines have focused on strategies to elicit such antibodies; however, the concern has been raised that previous influenza immunity may abrogate the induction of such broadly protective antibodies. We show here that prime-boost immunization can induce broadly neutralizing antibody responses in influenza-immune mice and ferrets that were previously infected or vaccinated. HA stem-directed antibodies were elicited in mice primed with a DNA vaccine and boosted with inactivated vaccine from H1N1 A/New Caledonia/20/1999 (1999 NC) HA regardless of preexposure. Similarly, gene-based vaccination with replication-defective adenovirus 28 (rAd28) and 5 (rAd5) vectors encoding 1999 NC HA elicited stem-directed neutralizing antibodies and conferred protection against unmatched 1934 and 2007 H1N1 virus challenge in influenza-immune ferrets. Indeed, previous exposure to certain strains could enhance immunogenicity: The strongest HA stem-directed immune response was observed in ferrets previously infected with a divergent 1934 H1N1 virus. These findings suggest that broadly neutralizing antibodies against the conserved stem region of HA can be elicited through vaccination despite previous influenza exposure, which supports the feasibility of developing stem-directed universal influenza vaccines for humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896678     DOI: 10.1126/scitranslmed.3004273

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  39 in total

1.  A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

Authors:  Karuppiah Muthumani; Darryl Falzarano; Emma L Reuschel; Colleen Tingey; Seleeke Flingai; Daniel O Villarreal; Megan Wise; Ami Patel; Abdullah Izmirly; Abdulelah Aljuaid; Alecia M Seliga; Geoff Soule; Matthew Morrow; Kimberly A Kraynyak; Amir S Khan; Dana P Scott; Friederike Feldmann; Rachel LaCasse; Kimberly Meade-White; Atsushi Okumura; Kenneth E Ugen; Niranjan Y Sardesai; J Joseph Kim; Gary Kobinger; Heinz Feldmann; David B Weiner
Journal:  Sci Transl Med       Date:  2015-08-19       Impact factor: 17.956

2.  Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Authors:  Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham
Journal:  Contemp Clin Trials       Date:  2015-08-12       Impact factor: 2.226

3.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

4.  Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Authors:  Florian Krammer; Rong Hai; Mark Yondola; Gene S Tan; Victor H Leyva-Grado; Alex B Ryder; Matthew S Miller; John K Rose; Peter Palese; Adolfo García-Sastre; Randy A Albrecht
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 5.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

6.  Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Authors:  Peter H Goff; Tomoko Hayashi; Luis Martínez-Gil; Maripat Corr; Brian Crain; Shiyin Yao; Howard B Cottam; Michael Chan; Irene Ramos; Dirk Eggink; Mitra Heshmati; Florian Krammer; Karen Messer; Minya Pu; Ana Fernandez-Sesma; Peter Palese; Dennis A Carson
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

7.  Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins.

Authors:  Guglielmo Lucchese; Giovanni Capone; Darja Kanduc
Journal:  Schizophr Bull       Date:  2013-01-31       Impact factor: 9.306

8.  The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.

Authors:  Tracey M Doyle; Bozena Jaentschke; Gary Van Domselaar; Anwar M Hashem; Aaron Farnsworth; Nicole E Forbes; Changgui Li; Junzhi Wang; Runtao He; Earl G Brown; Xuguang Li
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

9.  Getting to the heart of influenza.

Authors:  Jonathan W Yewdell; David J Spiro; Hana Golding; Helen Quill; Abraham Mittelman; Gary J Nabel
Journal:  Sci Transl Med       Date:  2013-06-26       Impact factor: 17.956

Review 10.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.